Atria Investments Inc Boosts Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Atria Investments Inc lifted its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 78.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,145 shares of the biopharmaceutical company’s stock after purchasing an additional 1,387 shares during the quarter. Atria Investments Inc’s holdings in Alnylam Pharmaceuticals were worth $865,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of the company. Allspring Global Investments Holdings LLC increased its holdings in Alnylam Pharmaceuticals by 572.0% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 143 shares during the period. Ashton Thomas Private Wealth LLC acquired a new position in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at about $26,000. Hollencrest Capital Management purchased a new stake in shares of Alnylam Pharmaceuticals in the third quarter worth about $29,000. Altitude Crest Partners Inc. acquired a new stake in Alnylam Pharmaceuticals during the first quarter worth about $30,000. Finally, Washington Trust Advisors Inc. purchased a new position in Alnylam Pharmaceuticals during the third quarter valued at approximately $42,000. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Trading Down 1.4 %

Shares of Alnylam Pharmaceuticals stock opened at $232.27 on Tuesday. Alnylam Pharmaceuticals, Inc. has a 1-year low of $141.98 and a 1-year high of $304.39. The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.69. The stock has a market cap of $29.96 billion, a P/E ratio of -88.65 and a beta of 0.39. The stock’s 50 day simple moving average is $274.53 and its 200-day simple moving average is $236.10.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The business had revenue of $500.90 million during the quarter, compared to the consensus estimate of $532.91 million. During the same period in the prior year, the firm posted $1.15 EPS. The firm’s quarterly revenue was down 33.3% compared to the same quarter last year. Analysts predict that Alnylam Pharmaceuticals, Inc. will post -2.22 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have commented on ALNY shares. Citigroup upped their price objective on Alnylam Pharmaceuticals from $291.00 to $342.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. Canaccord Genuity Group raised their price target on shares of Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the company a “buy” rating in a research report on Friday, November 1st. Needham & Company LLC reiterated a “buy” rating and issued a $320.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st. The Goldman Sachs Group raised shares of Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and increased their target price for the stock from $198.00 to $370.00 in a research note on Friday, August 16th. Finally, Cantor Fitzgerald restated a “neutral” rating and issued a $220.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, October 11th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and nineteen have assigned a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $298.09.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.